

Home

About ATTR amyloidosis

ATTR signs and symptoms

Diagnosing ATTR amyloidosis

Transthyretin amyloidosis (ATTR) is a systemic, progressive

and potentially fatal disease that is frequently under-recognised

Management approaches



Early suspicion can lead to timely diagnosis of ATTR amyloidosis and prompt treatment, which may slow disease progression^{1,4-6}

If you suspect ATTR amyloidosis, it is important to refer your patients to the National Amyloidosis Centre (NAC) to be assessed



It is important to suspect ATTR amyloidosis signs and symptoms to facilitate earlier diagnosis and treatment1

Recognise the signs and symptoms of ATTR amyloidosis

In most patients with ATTR-CM, misdiagnosis or delayed diagnosis may lead to irretrievable loss of quality of life and disease progression of polyneuropathic and cardiac symptoms^{1,6}

Early diagnosis and referral are essential

SEE THE SIGNS AND SYMPTOMS

(>)

DISCOVER DIAGNOSTIC TOOLS

ATTR=transthyretin amyloidosis; ATTR-CM=transthyretin amyloidosis with cardiomyopathy.

References: 1. Nativi-Nicolau JN, et al. Heart Fail Rev. 2022;27(3):785-793; 2. Adams D, et al. J Neurol. 2021;268(6):2109-2122; 3. Gertz MA, et al. BMC Fam Pract. 2020;21(1):198; 4. Gonzàlez-Duarte, Concieção I, and Amass L. Neuro Ther. 2020;9:135–149; 5. Keohane D, et al. Amyloid. 2017;24(1):30–36; 6. Rozenbaum MH, et al. J Comp Eff Res. 2021;10(11):927–938.

GB-62815



Legal Notice and Terms of Use Privacy Notice

ks traZeneca Corporate Site

Site Map

Contact us

The information on this website has been created and funded by AstraZeneca UK for educational purposes only. The content is intended for UK healthcare professionals and should not be used for diagnosing or treating a health problem or disease.